Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Shares Issued (2016 - 2025)

Viking Therapeutics (VKTX) has disclosed Shares Issued for 11 consecutive years, with $1.2 million as the latest value for Q4 2025.

  • Quarterly Shares Issued rose 14.02% to $1.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.5 million through Dec 2025, down 76.96% year-over-year, with the annual reading at $2.5 million for FY2025, 76.96% down from the prior year.
  • Shares Issued hit $1.2 million in Q4 2025 for Viking Therapeutics, up from $436000.0 in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $5.7 million in Q1 2021 to a low of -$1000.0 in Q3 2023.
  • Historically, Shares Issued has averaged $1.5 million across 5 years, with a median of $614000.0 in 2022.
  • Biggest five-year swings in Shares Issued: tumbled 97.57% in 2021 and later surged 251000.0% in 2024.
  • Year by year, Shares Issued stood at $66000.0 in 2021, then surged by 127.27% to $150000.0 in 2022, then grew by 25.33% to $188000.0 in 2023, then surged by 438.83% to $1.0 million in 2024, then increased by 14.02% to $1.2 million in 2025.
  • Business Quant data shows Shares Issued for VKTX at $1.2 million in Q4 2025, $436000.0 in Q3 2025, and $551000.0 in Q2 2025.